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 Introduction 
 Asthma is a chronic inflammatory airway disease 
characterized by episodes of reversible airway obstruc-
tion, bronchial hyperresponsiveness and chronic pulmo-
nary inflammation  [1] . In the last 3 decades, the preva-
lence of asthma has been increasing, particularly in chil-
dren. The last estimate of asthma prevalence was 300 
million worldwide  [1] .
 The imbalance in immune responses tending towards 
type 2 and inflammatory responses has been described to 
be of importance in the immunopathogenesis of asthma 
in children  [1, 2] . IL-33 is a relatively new member of the 
IL-1 family of cytokines that mediates both inflammatory 
and type 2 preallergenic responses. IL-33 secreted by epi-
thelial cells, by binding to its own receptor, ST2, activates 
the immune system  [3] . In mouse models, IL-33 has been 
found to amplify IgE synthesis, tryptase activity, eotaxin 
production, histamine release, mast cell degranulation 
and airway smooth-muscle contractility  [4–6] .
 Recent studies underscored the important role of IL-
33 in the pathogenesis of the severe steroid-resistant asth-
ma phenotype with  [7] or without fungal sensitization 
 [8] . Steroid treatment may reduce IL-13 and other type 2 
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 Abstract 
 Background: The role of IL-33, a member of the IL-1 family, 
in airway hyperresponsiveness and asthma has still to be ful-
ly understood.  Objectives : This study is aimed at investigat-
ing serum IL-33 in children with asthma and its association 
with asthma severity.  Methods: This age- and sex-matched 
case-control study comprised 61 children with asthma and 
63 healthy controls. The mean age of the participants was 
9.21 years (range: 6–14). Serum IL-33 was measured using 
ELISA and was compared between children with asthma and 
controls. In addition, the association of serum IL-33 with 
asthma severity was investigated.  Results: The level of se-
rum IL-33 was significantly higher in children with asthma 
than in controls (15.17 ± 32.3 vs. 0.61 ± 2.16 pg/ml; p = 0.028). 
It was significantly increased proportionately to asthma se-
verity, namely 9.92 ± 30.26 pg/ml in children with mild asth-
ma, 13.68 ± 29.27 pg/ml in children with moderate asthma 
and 31.92 ± 41.45 pg/ml in children with severe asthma (p = 
0.026).  Conclusion: Serum IL-33 is increased in children with 
asthma and is associated with disease severity. 
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immune responses but does not affect IL-33 expression in 
fibroblasts and airway smooth-muscle cells taken from 
airway biopsies of children with severe steroid-resistant 
asthma  [5, 7, 8] . In mouse models of allergic airway dis-
ease, the IL-33/ST2 axis induced airway remodeling inde-
pendent of IL-13  [8] . However, the association of serum 
IL-33 with asthma severity has still to be studied. We 
aimed to investigate the serum IL-33 in patients with 
asthma compared to controls and the association of se-
rum IL-33 with asthma severity.
 Materials and Methods 
 This age- and sex-matched case-control study was conducted 
on 124 children under the age of 18 years. The case group com-
prised 61 children with asthma; 63 healthy children free of any al-
lergic or other chronic diseases were included as controls. Controls 
were recruited via announcements at schools and in newspapers, 
while cases with asthma were recruited from the outpatient clinic 
for asthma and allergy of the Children’s Medical Center Hospital. 
A thorough history was taken and medical records were reviewed 
for recurrent wheezing, food allergy and atopic dermatitis. Forced 
expiratory volume in 1 s (FEV 1 ) was measured for all participants. 
Asthma was diagnosed and classified according to published 
guidelines  [9] . Following diagnosis, asthma severity was catego-
rized into mild (intermittent), moderate and severe. Patients with 
mild asthma were those with daytime symptoms on <2 days and 
night waking 3–4 times per week, an FEV 1 >80% of predicted as 
well as those experiencing minor limitations in their daily activi-
ties. Children with severe asthma had frequent daytime symptoms 
and night waking maybe every night, an FEV 1 <60% of predicted 
and experienced major limitations in their daily activities. Patients 
with moderate asthma had features between these two extremes.
 We also categorized the children as having controlled and un-
controlled asthma with respect to their medication needs for con-
trol of the disease. Children with controlled asthma had  ≤ 2 daily 
symptoms or reliever requirements per week and had had no night 
waking or activity limitation due to asthma during the last month 
while on adequate treatment. However, uncontrolled asthmatics 
had frequent daily symptoms and reliever requirements as well as 
night waking and activity limitations due to their asthma. The par-
ticipants and their parents received detailed information regarding 
the study protocol. Informed consent was obtained from the par-
ents of all participants. The institutional review board approved the 
study and the study protocol was in accordance with the guidelines 
laid down by the latest version of the Helsinki Declaration (2008).
 For the case group, the measurement of serum eosinophil 
count and IL-33 was done at times other than when the children 
were admitted for asthma attacks. The controls were free of any 
acute infectious disease at the time of sample collection. Five mil-
liliters of peripheral blood were collected from both patients and 
controls and were stored at –20   °   C for the measurement of IL-33. 
Serum IL-33 was measured using sandwich enzyme-linked immu-
nosorbent assay (ELISA, eBiosience cat. No. BMS2048). The sen-
sitivity of this ELISA kit was 0.2 pg/ml. The analysis was done ac-
cording to the manufacturer’s guideline.
 Statistical analyses were done using SPPS statistical software 
v18 (SPSS Inc., Chicago, Ill., USA). The Student t test was used to 
compare continuous variables and the Fisher exact test for categor-
ical variables between patients with asthma and controls. The 
Kruskal-Wallis test was used to test associations between IL-33 
serum levels and disease severity. p < 0.05 was considered statisti-
cally significant.
 Results 
 This case-control study comprised 124 children with a 
mean age of 9.21 years (range: 6–14 years). Male-to-fe-
male ratio was approximately 1: 1 with a total of 68 boys 
and 56 girls. The case and control groups were matched 
with respect to age and sex.  Table  1 shows the demo-
graphics of participants in the case and control groups. 
Children with asthma had significantly lower FEV 1 than 
their healthy peers (78.2 ± 8.15 vs. 91.1 ± 8.25%; p <0.001), 
while serum eosinophil count was higher in children with 
asthma (5.05 ± 3.01 vs. 2.14 ± 1.58%; p < 0.001). Asthma 
was mild in 29, moderate in 24 and severe in 8 children. 
Serum IL-33 was detectable in 45 children with asthma 
and in 45 in the control group. We were not able to detect 
serum IL-33 in 34 of the participants. Children with asth-
ma had a significantly higher level of serum IL-33 than 
the healthy children (15.17 ± 32.3 vs. 0.61 ± 2.16 pg/ml; 
p = 0.028). More severity of asthma and more serum IL-
33 were observed in children with asthma ( fig. 1 ,  2 ).
 Discussion 
 We found that children with asthma have higher se-
rum IL-33 levels compared to their healthy peers. The 
more severe the disease, the more serum IL-33 was de-
tected in blood samples taken from the children with 
asthma. These findings are in line with the results of pre-
 Table 1.  Demographics of the participants
Variable Asthma patients
(n = 61)
Controls
(n = 63)
p value
Males 38 (62.29) 30 (47.61) 0.108
Age, years 9.44 ± 2.17 9.97 ± 2.05 0.164
Eosinophils, % 5.05 ± 3.01 2.14 ± 1.58 <0.001
FEV1, % 78.2 ± 8.1 91.1 ± 8.25 <0.001
IL-33, pg/ml 15.17 ± 32.3 0.61 ± 2.16 0.028
Values are n (%) or means ± SD.
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vious studies. Guo et al.  [10] examined serum IL-33 in 45 
patients with asthma and 40 controls, and found that se-
rum IL-33 was higher in the asthma patients. Moreover, 
serum IL-33 was positively correlated with reticular base-
ment membrane thickening on bronchial biopsies and 
asthma severity, but negatively correlated with FEV 1 . 
Similarly, Raeiszadeh Jahromi et al.  [11]  demonstrated 
that serum IL-33 was higher in patients with asthma than 
in controls and that it had a negative correlation with 
FEV 1 and forced vital capacity. Interestingly, they showed 
that serum IL-33 is positively associated with the number 
of aeroallergen sensitizations. There exists a strong posi-
tive correlation between serum IL-33 and induced-spu-
tum IL-33  [12] . The level of IL-33 in sputum is also high-
er in patients with asthma than in healthy individuals 
 [12] .
 Serum IL-33 has been shown to be increased in allergic 
rhinitis more than in allergic asthma  [13, 14] . However, 
Asaka et al.  [14]  could not detect IL-33 in sera samples 
taken from patients with allergic rhinitis. They measured 
IL-33 in the nasal secretions of study participants instead, 
and found that IL-33 in the nasal secretions of allergic 
rhinitis patients was significantly higher than in controls 
and was also associated with total nasal symptom scores. 
Similarly, we were not able to detect serum IL-33 in 34 of 
our 124 participants. Of the children with asthma, serum 
IL-33 was not detectable in 16 patients with mild disease. 
However, we found that even children with mild asthma 
had significantly higher serum IL-33 compared to healthy 
controls.
 The important role of IL-33 in initiating airway hyper-
responsiveness and inducing airway remodeling has been 
shown mainly in studies on animal models. Airway 
smooth-muscle cells as well as innate type 2 lymphocyte 
cells and Th2 cells produce IL-33 in response to proin-
flammatory cytokines and aeroallergen exposure  [15] . In 
addition, type 2 cytokines are released from human T 
cells and innate lymphocyte cells cocultured with rhino-
virus entirely dependent on IL-33. This finding empha-
sizes the role of IL-33 in rhinovirus-induced asthma ex-
acerbation  [16] .
 IL-33 also acts as a chemoattractant for Th2 cells, lead-
ing to their accumulation in lung tissue and creating a vi-
cious cycle of allergic and inflammatory responses in the 
airways  [17] . Activation of the IL-33/ST2 axis leads to the 
activation of eosinophils, basophils and mast cells, induc-
es histamine and eotaxin release and increases tryptase 
activity in the airways and lung parenchyma  [5, 18] . IL-33 
has also been found to increased IgE production via IL-4, 
in a mouse model  [4] , and to enhance airway smooth-
muscle cell contractility  [5] . Altogether, IL-33 seems to be 
a potent inducer of inflammatory and allergic responses 
leading to airway hyperresponsiveness and asthma.
 Increased expression of IL-33 has also been linked to 
poor control of asthma and the steroid-resistant asthma 
phenotype  [7] . In patients with steroid-resistant asthma, 
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 Fig. 1. Serum IL-33 was 9.92 ± 30.26 pg/ml in children with mild 
asthma, 13.68 ± 29.27 pg/ml in children with moderate asthma and 
31.92 ± 41.45 pg/ml in children with severe asthma. Serum IL-33 
was the least in asthmatic children with mild disease. However, 
serum IL-33 was significantly higher in asthmatics than in the con-
trol group (9.92 ± 30.26 vs. 0.61 ± 2.16 pg/ml; p = 0.016). Simi-
larly, those with severe asthma had significantly higher IL-33 com-
pared to those with moderate and mild asthma. The Kruskal-Wal-
lis test was performed to determine the association of the IL-33 
serum levels in the 3 groups with disease severity, which led to 
significant results (p < 0.05). Patients with moderate and severe 
asthma had significantly higher serum IL-33 compared to patients 
with mild asthma (13.68 ± 29.27 vs. 9.92± 30.26 pg/ml; p = 0.03 
and 31.92± 41.45 vs. 9.92± 30.26 pg/ml; p = 0.002).  *  p < 0.05. 
 Fig. 2. Participants with uncontrolled asthma had significantly 
higher serum levels of IL-33 compared to those with controlled 
asthma (9.92 ± 30.26 vs. 19.76 ± 34.04 pg/ml; p = 0.013). 
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steroid treatment may reduce the production of proin-
flammatory and type 2 cytokines by airway fibroblasts but 
it does not affect IL-33 expression significantly  [8] . IL-33 
itself induces the production of collagen and fibronectin 
by fibroblasts and promotes airway remodeling  [8] . These 
in vitro findings are in line with the results of human 
studies in which serum IL-33 has been positively corre-
lated with basement membrane thickness on airway bi-
opsies  [10] . Given the results of our study and the impor-
tant role of IL-33 in steroid-resistant asthma, IL-33 can 
be considered as a marker of asthma severity. However, 
due to the design of our study, we are unable to draw a 
causal relationship between increased serum IL-33 and 
the severity of asthma. Increased IL-33 can still be consid-
ered as a consequence of asthma severity, bronchial dam-
age and chronic airway inflammation. In this study, in-
haled corticosteroids were the mainstay of therapy, but 
with an increase in asthma severity, a combination of 
long-acting β 2 agonists and leukotriene receptor antago-
nists was used. Unfortunately, we did not record the exact 
medications used and their dosage. Hence, another limi-
tation of this study is the absence of investigation of the 
possible effect of each medication on serum IL-33. The 
strengths of the study are its concise design and the 
matching of cases and controls. However, several limita-
tions should be acknowledged. As stated, no causality link 
can be drawn between the increased expression of IL-33 
and asthma severity. Moreover, serum IL-33 was unde-
tectable in a considerable number of participants; this 
lowers the power of the study. Further studies are needed 
to shed light on the exact role of IL-33 in severe asthma 
and to pave the way for more efficacious therapies.
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